A Look at Leading Solar Energy Storage Brands
GREENACRE, Australia, Nov. 26, 2025 /PRNewswire/ -- In 2025, Australia's home battery storage sector has seen explosive growth. Since July, the federal Cheaper Home Batteries Program has driven the installation of around 100,000 household battery...
Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy
– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's...
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study...
Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation,...
Datasea Inc. Issues Statement Regarding Recent Market Activity
BEIJING, Nov. 18, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company") ,a Nevada-based high-tech enterprise engaged in acoustic technologies and AI multimodal digitalization, today issues a brief statement regarding recent...
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and sustained hematologic responses – - A novel mechanism targeting NEK7 and NLRP3 inflammasomes shows promise across multiple myeloid neoplasms – - Preclinical...
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as...
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress
CHENGDU, China, Nov. 10, 2025 /PRNewswire/ -- From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This conference was jointly organized by the Chinese Anti-Cancer Association (CACA),...
EBR Systems Achieves First Enrollments in the WiSE-UP Study for Heart Failure Patients
The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: The first two patients have now been enrolled in the WiSE-UP...
Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naive patients with differentiated thyroid cancer – TOKYO, Oct. 31, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Sunao Fujioka;...